ELIXA enrolled 6,068 diabetic patients with recent heart attacks to test whether the GLP-1 receptor agonist lixisenatide is safe and potentially beneficial for cardiovascular outcomes.
6,068 patients across 49 countriesThe first cardiovascular outcomes trial for any GLP-1 receptor agonist, setting the stage for understanding heart safety of the most prescribed peptide drug class
What the researchers found
The ELIXA trial enrolled 6,068 patients with type 2 diabetes and recent acute coronary syndrome across 49 countries to evaluate whether the GLP-1 receptor agonist peptide lixisenatide affects cardiovascular outcomes. This paper reports the study design and baseline characteristics: participants had a mean age of 60.3 years, mean BMI of 30.2, and average diabetes duration of 9.3 years. The qualifying event was myocardial infarction in 83% and unstable angina in 17%.
ELIXA was the first major cardiovascular outcomes trial of a GLP-1 receptor agonist, designed to evaluate both safety and potential cardiovascular benefit in a high-risk diabetic population.
Why it matters
This trial was pivotal for the GLP-1 receptor agonist drug class. Following FDA requirements for cardiovascular safety testing of diabetes drugs (post-rosiglitazone), ELIXA set the stage for understanding whether GLP-1 peptide therapies — now among the most prescribed medications worldwide — are safe or beneficial for the heart. The results of this and subsequent GLP-1 RA cardiovascular trials fundamentally shaped treatment guidelines for type 2 diabetes.
How the study worked
Randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. 6,068 patients with T2DM and recent ACS were randomized to lixisenatide or placebo across 49 countries. Enrollment ran from July 2010 to August 2013. The primary endpoint was a composite of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina. Safety data on hypoglycemia, pancreatitis, and malignancy were systematically collected.
Who was studied
6,068 patients with T2DM and recent ACS; 69% male, 75% white, mean age 60.3 years, mean BMI 30.2, mean diabetes duration 9.3 years
What this study cannot tell us
This is a design and baseline characteristics paper — it does not report outcomes. The study population is specifically high-risk (recent ACS), so findings may not generalize to lower-risk diabetic patients. As a trial of a single GLP-1 RA (lixisenatide), results cannot be assumed to apply to other agents in the class like semaglutide or liraglutide.
How to read the evidence
This is a strong-grade study in terms of design — a large, multinational, double-blind, placebo-controlled randomized trial. However, this specific paper reports only the design and baseline characteristics, not outcomes.
When this study was published
Published in 2015, this design paper preceded the ELIXA results publication. The trial results have since been reported and are now part of the established evidence base for GLP-1 RA cardiovascular safety.
The bigger picture
ELIXA was a landmark trial in the GLP-1 receptor agonist story. While subsequent trials (LEADER with liraglutide, SUSTAIN-6 with semaglutide) ultimately showed cardiovascular benefits for some GLP-1 RAs, ELIXA was the first to provide rigorous safety data for the class. This trial helped build confidence that peptide-based diabetes drugs were at minimum cardiovascularly safe, paving the way for the current revolution in GLP-1-based therapies.
Questions still open
- How did lixisenatide's cardiovascular outcomes compare to the subsequent trials of liraglutide and semaglutide?
- Do the cardiovascular effects of GLP-1 receptor agonists differ based on whether patients have acute vs. chronic cardiovascular disease?
- What explains the potential differences in cardiovascular benefit between short-acting (lixisenatide) and long-acting (semaglutide) GLP-1 RAs?
Common questions
What is lixisenatide and how does it relate to drugs like Ozempic?
Why was this cardiovascular trial required?
Read the original research
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
American heart journal, 169(5), 631-638.e7
Citation
Bentley-Lewis, Rhonda; Aguilar, David; Riddle, Matthew C; Claggett, Brian; Diaz, Rafael; Dickstein, Kenneth; Gerstein, Hertzel C; Johnston, Peter; Køber, Lars V; Lawson, Francesca; Lewis, Eldrin F; Maggioni, Aldo P; McMurray, John J V; Ping, Lin; Probstfield, Jeffrey L; Solomon, Scott D; Tardif, Jean-Claude; Wu, Yujun; Pfeffer, Marc A. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.. American heart journal, 169(5), 631-638.e7. https://doi.org/10.1016/j.ahj.2015.02.002